Alkermes spikes on first Phase III ALKS 5461 depression data
This article was originally published in Scrip
The Alkermes drug ALKS 5461 showed rapid onset and continued improvement in major depressive disorder (MDD) in the first Phase III clinical trial for the novel, oral therapy, which was consistent with previously positive Phase II results.
You may also be interested in...
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.